multi-peptide cmv-modified vaccinia ankara vaccine
Vaccineexperimental
Clinical trial activity
11 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jan 5, 2014 (NCT01941056)
Timeline
Indications
Studied for
- Bone Marrow Transplantation · Phase 2
- Cytomegalovirus Infections · Phase 2
- Healthy Volunteers · Phase 1
- Hematopoietic Stem Cell Transplantation · Phase 2
- Hodgkin Disease · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 2
- Leukemia, Myeloid · Phase 1
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Lymphadenopathy · Phase 2
- Lymphoma · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Myeloproliferative Disorders · Phase 2
- Neoplasms · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Primary Myelofibrosis · Phase 2
- Tissue Donors · Phase 2
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- multi-cmv epitope modified vaccinia ankara vaccine
- multi-peptide cmv-modified vaccinia ankara vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07020533 | Phase 1 | May 8, 2026 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT06735690 | Early Phase 1 (Phase 1) | Aug 23, 2025 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT06059391 | Phase 2 | Dec 25, 2023 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT05801913 | Phase 1 | Sep 29, 2023 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT05432635 | Phase 1 | Sep 7, 2022 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT04060277 | Phase 2 | Dec 1, 2019 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT03438344 | Phase 2 | Dec 31, 2018 | City of Hope National Medical Center |
| NCT03354728 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2018 | City of Hope National Medical Center |
| NCT03560752 | Phase 2 | Aug 20, 2018 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT02506933 | Phase 2 | Nov 5, 2015 | City of Hope National Medical Center, Fortress Biotech, National Cancer Institute (NCI) |
| NCT01941056 | Phase 1 | Jan 5, 2014 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 11 | 11 | 2 | 2014 |
| National Cancer Institute (NCI) | Government | 9 | 0 | 2 | 2014 |
| Fortress Biotech | For profit | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1